Inhibitors of HMG-CoA reductase: Current and future prospects

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 11, 2009, Pages 1272-1283

  Singh, Narender ^a   Tamariz, Joaquín ^b   Chamorro, Germán ^b   Medina Franco, Jose L ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

asarone; 3 hydroxy 3 methylglutaryl coenzyme A reductase; Cardiovascular disease; Cholesterol; Low density lipoproteins; Side effects; Statins; Structure based drug design

Indexed keywords

ALPHA ASARONE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN;

CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTHALPY; ENTROPY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PLEIOTROPY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RHABDOMYOLYSIS; SHORT SURVEY; TESTIS DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANISOLES; ANTICHOLESTEREMIC AGENTS; BINDING SITES; CARDIOVASCULAR DISEASES; CHOLESTEROL; DATABASES, PROTEIN; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73349085890     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709789878105     Document Type: Short Survey

References (131)

1. American Heart Association. http://www.americanheart.org (Accessed July 28, 2009).
2. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T.B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'Donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009, 119, e21-181.
3. Murray, C.J.; Lopez, A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997, 349, 1269-76.
4. Rosamond, W.D.; Chambless, L.E.; Folsom, A.R.; Cooper, L.S.; Conwill, D.E.; Clegg, L.; Wang, C.H.; Heiss, G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N. Engl. J. Med., 1998, 339, 861-7.
5. Kidd, J. Life after statin patent expiries. Nat. Rev. Drug Discov., 2006, 5, 813-4.
6. Edwards, P.A.; Ericsson, J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem., 1999, 68, 157-85.
7. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 343, 425-30.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002, 106, 3143-421.
9. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr., 1999, 19, 141-72.
10. Willnow, T.E. The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. J. Mol. Med., 1999, 77, 306-15.
11. Ross, S.D.; Allen, I.E.; Connelly, J.E.; Korenblat, B.M.; Smith, M.E.; Bishop, D.; Luo, D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch. Intern. Med., 1999, 159, 1793-802.
12. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest., 2002, 109, 1125-31.
13. Brown, M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232, 34-47.
14. Decision Resources, Inc. http://www.decisionresources.com (Accessed July 28, 2009).
15. Maddrey, W.C. Drug-induced hepatotoxicity: 2005. J. Clin. Gastroenterol., 2005, 39, S83-9.
16. Maron, D.J.; Fazio, S.; Linton, M.F. Current perspectives on statins. Circulation, 2000, 101, 207-13.
17. Holstein, S.A.; Hohl, R.J. Isoprenoids: remarkable diversity of form and function. Lipids., 2004, 39, 293-309.
18. Tobert, J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2, 517-26.
19. Friesen, J.A.; Rodwell, V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol., 2004, 5, 248.
20. Bochar, D.A.; Stauffacher, C.V.; Rodwell, V.W. Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mol. Genet. Metab., 1999, 66, 122-7.
21. Hedl, M.; Tabernero, L.; Stauffacher, C.V.; Rodwell, V.W. Class II 3-hydroxy-3-methylglutaryl coenzyme A reductases. J. Bacteriol., 2004, 186, 1927-32.
22. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292, 1160-4.
23. Istvan, E.S.; Palnitkar, M.; Buchanan, S.K.; Deisenhofer, J. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J., 2000, 19, 819-30.
24. Park, W.K.; Kennedy, R.M.; Larsen, S.D.; Miller, S.; Roth, B.D.; Song, Y.; Steinbaugh, B.A.; Sun, K.; Tait, B.D.; Kowala, M.C.; Trivedi, B.K.; Auerbach, B.; Askew, V.; Dillon, L.; Hanselman, J.C.; Lin, Z.; Lu, G.H.; Robertson, A.; Sekerke, C. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1151-6.
25. Pfefferkorn, J.A.; Choi, C.; Larsen, S.D.; Auerbach, B.; Hutchings, R.; Park, W.; Askew, V.; Dillon, L.; Hanselman, J.C.; Lin, Z.; Lu, G.H.; Robertson, A.; Sekerke, C.; Harris, M.S.; Pavlovsky, A.; Bainbridge, G.; Caspers, N.; Kowala, M.; Tait, B.D. Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5- (4-methylbenzylcarbamoyl)-2H -pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia. J. Med. Chem., 2008, 51, 31-45.
26. Pfefferkorn, J.A.; Choi, C.; Song, Y.; Trivedi, B.K.; Larsen, S.D.; Askew, V.; Dillon, L.; Hanselman, J.C.; Lin, Z.; Lu, G.; Robertson, A.; Sekerke, C.; Auerbach, B.; Pavlovsky, A.; Harris, M.S.; Bainbridge, G.; Caspers, N. Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4531-7.
27. Pfefferkorn, J.A.; Song, Y.; Sun, K.L.; Miller, S.R.; Trivedi, B.K.; Choi, C.; Sorenson, R.J.; Bratton, L.D.; Unangst, P.C.; Larsen, S.D.; Poel, T.J.; Cheng, X.M.; Lee, C.; Erasga, N.; Auerbach, B.; Askew, V.; Dillon, L.; Hanselman, J.C.; Lin, Z.; Lu, G.; Robertson, A.; Olsen, K.; Mertz, T.; Sekerke, C.; Pavlovsky, A.; Harris, M.S.; Bainbridge, G.; Caspers, N.; Chen, H.; Eberstadt, M. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4538-44.
28. Sarver, R.W.; Bills, E.; Bolton, G.; Bratton, L.D.; Caspers, N.L.; Dunbar, J.B.; Harris, M.S.; Hutchings, R.H.; Kennedy, R.M.; Larsen, S.D.; Pavlovsky, A.; Pfefferkorn, J.A.; Bainbridge, G. Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Med. Chem., 2008, 51, 3804-13.
29. Tabernero, L.; Bochar, D.A.; Rodwell, V.W.; Stauffacher, C.V. Substrate-induced closure of the flap domain in the ternary complex structures provides insights into the mechanism of catalysis by 3-hydroxy-3-methylglutaryl- CoA reductase. Proc. Natl. Acad. Sci. USA, 1999, 96, 7167-71.
30. Tabernero, L.; Rodwell, V.W.; Stauffacher, C.V. Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase. J. Biol. Chem., 2003, 278, 19933-8.
31. Istvan, E.S. Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architectures. Curr. Opin. Struct. Biol., 2001, 11, 746-51.
32. Hampton, R.Y.; Rine, J. Regulated degradation of HMG-CoA reductase, an integral membrane protein of the endoplasmic reticulum, in yeast. J. Cell Biol., 1994, 125, 299-312.
33. Meigs, T.E.; Simoni, R.D. Regulated degradation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase in permeabilized cells. J. Biol. Chem., 1992, 267, 13547-52.
34. Meigs, T.E.; Simoni, R.D. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys., 1997, 345, 1-9.
35. Brown, M.S.; Faust, J.R.; Goldstein, J.L.; Kaneko, I.; Endo, A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem., 1978, 253, 1121-8.
36. Endo, A.; Kuroda, M.; Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett., 1976, 72, 323-6.
37. Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo), 1976, 29, 1346-8.
38. Tanzawa, K.; Endo, A. Kinetic analysis of the reaction catalyzed by rat-liver 3-hydroxy-3-methylglutaryl-coenzyme-A reductase using two specific inhibitors. Eur. J. Biochem., 1979, 98, 195-201.
39. Alberts, A.W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; Patchett, A.; Monaghan, R.; Currie, S.; Stapley, E.; Albers-Schonberg, G.; Hensens, O.; Hirshfield, J.; Hoogsteen, K.; Liesch, J.; Springer, J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA, 1980, 77, 3957-61.
40. Willard, A.K. 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-e thyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones. U.S. Patent 4,293,496. 1981.
41. Tsujita, Y.; Kuroda, M.; Shimada, Y.; Tanzawa, K.; Arai, M.; Kaneko, I.; Tanaka, M.; Masuda, H.; Tarumi, C.; Watanabe, Y.; et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta, 1986, 877, 50-60.
42. Kathawala, F.G. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof. U.S. Patent 4,739,073. 1988.
43. Kathawala, F.G. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev., 1991, 11, 121-46.
44. Roth, B.D. Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 4,681,893. 1987.
45. Corsini, A.; Arnaboldi, L.; Raiteri, M.; Quarato, P.; Faggiotto, A.; Paoletti, R.; Fumagalli, R. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol. Res., 1996, 33, 55-61.
46. Watanabe, M.; Koike, H.; Ishiba, T.; Okada, T.; Seo, S.; Hirai, K. Synthesis and biological activity of methanesulfonamide pyrimidine-and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem., 1997, 5, 437-44.
47. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-9.
48. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med., 1996, 335, 1001-9.
49. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med., 1998, 339, 1349-57.
50. Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R.; MacFarlane, P.W.; McKillop, J.H.; Packard, C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 1995, 333, 1301-7.
51. Downs, J.R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D.R.; Beere, P.A.; Langendorfer, A.; Stein, E.A.; Kruyer, W.; Gotto, A.M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279, 1615-22.
52. Nissen, S.E.; Tuzcu, E.M.; Schoenhagen, P.; Brown, B.G.; Ganz, P.; Vogel, R.A.; Crowe, T.; Howard, G.; Cooper, C.J.; Brodie, B.; Grines, C.L.; DeMaria, A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, 291, 1071-80.
53. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M., Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359, 2195-207.
54. Carbonell, T.; Freire, E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry (Mosc), 2005, 44, 11741-8.
55. Cueto, R.; Valdivielso, P.; Lucena, M.I.; Garcia-Arias, C.; Andrade, R.J.; Gonzalez-Santos, P.; Lucena, M.I. Statins: Hepatic Disease and Hepatotoxicity Risk. Open Gastroenterol. J., 2008, 2, 18-23.
56. Holdgate, G.A.; Ward, W.H.; McTaggart, F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Trans., 2003, 31, 528-31.
57. Istvan, E.S. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am. Heart J., 2002, 144, S27-32.
58. Mason, R.P.; Walter, M.F.; Day, C.A.; Jacob, R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am. J. Cardiol., 2005, 96, 11F-23F.
59. Thilagavathi, R.; Kumar, R.; Aparna, V.; Sobhia, M.E.; Gopalakrishnan, B.; Chakraborti, A.K. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA). Bioorg. Med. Chem. Lett., 2005, 15, 1027-32.
60. Vaughan, C.J.; Gotto, A.M., Jr. Update on statins: 2003. Circulation, 2004, 110, 886-92.
61. White, C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol., 2002, 42, 963-70.
62. Consumer Health Reports. http://www.consumerreports.org/health/ resources/pdf/best-buy-drugs/StatinsUpdate-FINAL.pdf (Accessed July 28, 2009).
63. Corsini, A.; Bellosta, S.; Baetta, R.; Fumagalli, R.; Paoletti, R.; Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther., 1999, 84, 413-28.
64. New light on statin side effects. What recent research on the cholesterol drugs means to you. Heart Advis., 2005, 8, 3.
65. Golomb, B.A.; Evans, M.A. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs, 2008, 8, 373-418.
66. Silva, M.A.; Swanson, A.C.; Gandhi, P.J.; Tataronis, G.R. Statin-related adverse events: a meta-analysis. Clin. Ther., 2006, 28, 26-35.
67. Singh, S. Drug induced pancreatitis might be a class effect of statin drugs. J. Pancreas, 2005, 6, 380; author reply -1.
68. Skottheim, I.B.; Gedde-Dahl, A.; Hejazifar, S.; Hoel, K.; Asberg, A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur. J. Pharm. Sci., 2008, 33, 317-25.
69. Tiwari, A. An overview of statin-associated proteinuria. Drug Discov. Today, 2006, 11, 458-64.
70. Danesh, F.R.; Anel, R.L.; Zeng, L.; Lomasney, J.; Sahai, A.; Kanwar, Y.S. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch. Immunol. Ther. Exp. (Warsz), 2003, 51, 139-48.
71. Danesh, F.R.; Kanwar, Y.S. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J., 2004, 18, 805-15.
72. Davignon, J. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004, 109, III39-43.
73. Endres, M. Statins: potential new indications in inflammatory conditions. Atheroscler. Suppl., 2006, 7, 31-5.
74. Jasinska, M.; Owczarek, J.; Orszulak-Michalak, D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep., 2007, 59, 483-99.
75. Lahera, V.; Goicoechea, M.; de Vinuesa, S.G.; Miana, M.; de las Heras, N.; Cachofeiro, V.; Luno, J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem., 2007, 14, 243-8.
76. Liao, J.K. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol., 2002, 86, 5-18.
77. Liao, J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol., 2005, 96, 24F-33F.
78. Liao, J.K.; Laufs, U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 89-118.
79. Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med., 2008, 14, 37-44.
80. Weitz-Schmidt, G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci., 2002, 23, 482-6.
81. Graham, D.J.; Staffa, J.A.; Shatin, D.; Andrade, S.E.; Schech, S.D.; La Grenade, L.; Gurwitz, J.H.; Chan, K.A.; Goodman, M.J.; Platt, R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 2004, 292, 2585-90.
82. Sica, D.A.; Gehr, T.W. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Curr. Opin. Nephrol. Hypertens, 2002, 11, 123-33.
83. Davidson, M.H. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin. Investig. Drugs, 2002, 11, 125-41.
84. Quirk, J.; Thornton, M.; Kirkpatrick, P. Rosuvastatin calcium. Nat. Rev. Drug Discov., 2003, 2, 769-70.
85. Mason, R.P. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am. J. Cardiol., 2006, 98, 34P-41P.
86. Nezasa, K.; Higaki, K.; Takeuchi, M.; Nakano, M.; Koike, M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica, 2003, 33, 379-88.
87. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol., 2005, 19, 117-25.
88. Bellosta, S.; Paoletti, R.; Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation, 2004, 109, III50-7.
89. Field, F.J.; Born, E.; Mathur, S.N. Effect of micellar beta-sitosterol on cholesterol metabolism in CaCo-2 cells. J. Lipid Res., 1997, 38, 348-60.
90. Menendez, R.; Amor, A.M.; Rodeiro, I.; Gonzalez, R.M.; Gonzalez, P.C.; Alfonso, J.L.; Mas, R. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch. Med. Res., 2001, 32, 8-12.
91. Man, R.Y.; Lynn, E.G.; Cheung, F.; Tsang, P.S.; O, K. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol. Cell. Biochem., 2002, 233, 153-8.
92. Raju, J.; Bird, R.P. Diosgenin, a naturally occurring steroid [corrected] saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells. Cancer Lett., 2007, 255, 194-204.
93. Liu, L.; Yeh, Y.Y. S-alk(en)yl cysteines of garlic inhibit cholesterol synthesis by deactivating HMG-CoA reductase in cultured rat hepatocytes. J. Nutr., 2002, 132, 1129-34.
94. Parker, R.A.; Pearce, B.C.; Clark, R.W.; Gordon, D.A.; Wright, J.J. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutarylcoenzyme A reductase. J. Biol. Chem., 1993, 268, 11230-8.
95. Qureshi, A.A.; Mo, H.; Packer, L.; Peterson, D.M. Isolation and identification of novel tocotrienols from rice bran with hypocholesterolemic, antioxidant, and antitumor properties. J. Agric. Food Chem., 2000, 48, 3130-40.
96. St-Onge, M.P.; Farnworth, E.R.; Jones, P.J. Consumption of fermented and nonfermented dairy products: effects on cholesterol concentrations and metabolism. Am. J. Clin. Nutr., 2000, 71, 674-81.
97. Sung, J.H.; Lee, S.J.; Park, K.H.; Moon, T.W. Isoflavones inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase in vitro. Biosci. Biotechnol. Biochem., 2004, 68, 428-32.
98. Subbaiah, P.V.; Sowa, J.M.; Singh, D.K. Sphingolipids and cellular cholesterol homeostasis. Effect of ceramide on cholesterol trafficking and HMG CoA reductase activity. Arch. Biochem. Biophys., 2008, 474, 32-8.
99. Singh, D.K.; Banerjee, S.; Porter, T.D. Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells. J. Nutr. Biochem., 2008. in press (doi:10.1016/j.jnutbio.2008.07.011).
100. Bradfute, D.L.; Simoni, R.D. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J. Biol. Chem., 1994, 269, 6645-50.
101. Suzukawa, M.; Nakamura, H. Effect of ketanserin tartrate on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts. Eur. J. Clin. Pharmacol., 1990, 39, 217-20.
102. Harada-Shiba, M.; Tajima, S.; Yamamoto, A. Response of 3-hydroxy-3-methylglutaryl CoA reductase to l-triiodothyronine in cultured fibroblasts from FH homozygotes. Atherosclerosis, 1995, 113, 91-8.
103. Inoue, S.; Bar-Nun, S.; Roitelman, J.; Simoni, R.D. Inhibition of degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo by cysteine protease inhibitors. J. Biol. Chem., 1991, 266, 13311-7.
104. Volpe, J.J.; Goldberg, R.I. Effect of tunicamycin on 3-hydroxy-3- methylglutaryl coenzyme A reductase in C-6 glial cells. J. Biol. Chem., 1983, 258, 9220-6.
105. Panini, S.R.; Sexton, R.C.; Gupta, A.K.; Parish, E.J.; Chitrakorn, S.; Rudney, H. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis by oxylanosterols. J. Lipid Res., 1986, 27, 1190-204.
106. Trzaskos, J.M.; Magolda, R.L.; Favata, M.F.; Fischer, R.T.; Johnson, P.R.; Chen, H.W.; Ko, S.S.; Leonard, D.A.; Gaylor, J.L. Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 15 alpha-fluorolanost-7-en-3 beta-ol. A mechanism-based inhibitor of cholesterol biosynthesis. J. Biol. Chem., 1993, 268, 22591-9.
107. Gupta, A.K.; Sexton, R.C.; Rudney, H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J. Lipid Res., 1989, 30, 379-86.
108. Berkhout, T.A.; Simon, H.M.; Patel, D.D.; Bentzen, C.; Niesor, E.; Jackson, B.; Suckling, K.E. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem., 1996, 271, 14376-82.
109. Medina-Franco, J.L.; Lopez-Vallejo, F.; Rodriguez-Morales, S.; Castillo, R.; Chamorro, G.; Tamariz, J. Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase. Bioorg. Med. Chem. Lett., 2005, 15, 989-94.
110. Baxter, R.M.; Dandiya, P.C.; Kandel, S.I.; Okany, A.; Walker, G.C. Separation of the hypnotic potentiating principles from the essential oil of Acorus calamus L. of Indian origin by liquid-gas chromatography. Nature, 1960, 185, 466-67.
111. Belova, L.F.; Alibekov, S.D.; Baginskaia, A.I.; Sokolov, S.; Pokrovskaia, G.V. Asarone and its biological properties. Farmakol. Toksikol., 1985, 48, 17-20.
112. Rodriguez-Paez, L.; Juarez-Sanchez, M.; Antunez-Solis, J.; Baeza, I.; Wong, C. Alpha-asarone inhibits HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats. Phytomedicine, 2003, 10, 397-404.
113. Chamorro, G.; Garduno, L.; Sanchez, A.; Labarrios, F.; Salazar, M.; Martinez, E.; Diaz, F.; Tamariz, J. Hypolipidaemic activity of dimethoxy unconjugated propenyl side-chain analogs of α-asarone in mice. Drug Dev. Res., 1998, 43, 105-8.
114. Cruz, A.; Garduno, L.; Salazar, M.; Martinez, E.; Diaz, F.; Chamorro, G.; Tamariz, J. High hypolipidemic activity of saturated side-chain α-asarone analogs. Med. Chem. Res., 2001, 10, 587-95.
115. Cruz, A.; Garduno, L.; Salazar, M.; Martinez, E.; Jimenez-Vazquez, H.A.; Diaz, F.; Chamorro, G.; Tamariz, J. Synthesis and hypolipidemic activity of modified side chain α-asarone homologues. Arzneimittelforschung, 2001, 51, 535-44.
116. Cruz, M.D.C.; Salazar, M.; Garciafigueroa, Y.; Hernandez, D.; Diaz, F.; Chamorro, G.; Tamariz, J. Hypolipidemic Activity of New Phenoxyacetic Derivatives Related to alpha-Asarone with Minimal Pharmacophore Features. Drug Dev. Res., 2003, 60, 186-95.
117. Labarrios, F.; Garduno, L.; Vidal, M.R.; Garcia, R.; Salazar, M.; Martinez, E.; Diaz, F.; Chamorro, G.; Tamariz, J. Synthesis and hypolipidaemic evaluation of a series of alpha-asarone analogues related to clofibrate in mice. J. Pharm. Pharmacol., 1999, 51, 1-7.
118. Zuniga, C.; Garduno, L.; del Carmen Cruz, M.; Salazar, M.; Perez-Pasten, R.; Chamorro, G.; Labarrios, F.; Tamariz, J. Design of new potent hypolipidemic agents with the synergistic structural properties of alpha-asarone and fibrates. Drug Dev. Res., 2005, 64, 28-40.
119. Zhang, Q.Y.; Wan, J.; Xu, X.; Yang, G.F.; Ren, Y.L.; Liu, J.J.; Wang, H.; Guo, Y. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening. J. Comb. Chem., 2007, 9, 131-8.
120. Garcia, I.; Munteanu, C.R.; Fall, Y.; Gomez, G.; Uriarte, E.; Gonzalez-Diaz, H. QSAR and complex network study of the chiral HMGR inhibitor structural diversity. Bioorg. Med. Chem., 2009, 17, 165-75.
121. da Silva, V.B.; Taft, C.A.; Silva, C.H. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. J. Phys. Chem. A., 2008, 112, 2007-11.
122. Bratton, L.D.; Auerbach, B.; Choi, C.; Dillon, L.; Hanselman, J.C.; Larsen, S.D.; Lu, G.; Olsen, K.; Pfefferkorn, J.A.; Robertson, A.; Sekerke, C.; Trivedi, B.K.; Unangst, P.C. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase. Bioorg. Med. Chem., 2007, 15, 5576-89.
123. Saxena, M.; Soni, L.K.; Gupta, A.K.; Wakode, S.R.; Saxena, A.K.; Kaskhedikar, S.G. Development of pharmacophoric model of condensed pyridine and pyrimidine analogs as hydroxymethyl glutaryl coenzyme A reductase inhibitors. Indian J. Biochem. Biophys., 2006, 43, 32-6.
124. Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Sakashita, M.; Kitahara, M.; Sakoda, R. Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett., 2001, 11, 1285-8.
125. Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Kitahara, M.; Sakashita, M.; Sakoda, R. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem., 2001, 9, 2727-43.
126. Pak, V.V.; Kim, S.H.; Koo, M.; Lee, N.; Shakhidoyatov, K.M.; Kwon, D.Y. Peptide design of a competitive inhibitor for HMG-CoA reductase based on statin structure. Biopolymers, 2006, 84, 586-94.
127. Pak, V.V.; Koo, M.; Kim, M.J.; Yang, H.J.; Yun, L.; Kwon, D.Y. Modeling an active conformation for linear peptides and design of a competitive inhibitor for HMG-CoA reductase. J. Mol. Recognit., 2008, 21, 224-32.
128. Pak, V.V.; Koo, M.; Kim, M.J.; Yun, L.; Kwon, D.Y. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg. Med. Chem., 2008, 16, 1309-18.
129. Pak, V.V.; Koo, M.; Yun, L.; Kwon, D.Y. Recognized sequence and conformation in design of linear peptides as a competitive inhibitor for HMG-CoA reductase. J. Mol. Recognit., 2007, 20, 197-203.
130. Masters, B.A.; Palmoski, M.J.; Flint, O.P.; Gregg, R.E.; Wang-Iverson, D.; Durham, S.K. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol. Appl. Pharmacol., 1995, 131, 163-74.
131. Ahmad, S.; Madsen, C.S.; Stein, P.D.; Janovitz, E.; Huang, C.; Ngu, K.; Bisaha, S.; Kennedy, L.J.; Chen, B.C.; Zhao, R.; Sitkoff, D.; Monshizadegan, H.; Yin, X.; Ryan, C.S.; Zhang, R.; Giancarli, M.; Bird, E.; Chang, M.; Chen, X.; Setters, R.; Search, D.; Zhuang, S.; Nguyen-Tran, V.; Cuff, C.A.; Harrity, T.; Darienzo, C.J.; Li, T.; Reeves, R.A.; Blanar, M.A.; Barrish, J.C.; Zahler, R.; Robl, J.A. (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1, 2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3- methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. J. Med. Chem., 2008, 51, 2722-33.